FibroBiologics, Inc. Common Stock (FBLG) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.43 (-3.70%), Market cap $0.01B, 52-week low–high $0.20 ~ $2.28.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headqu
Financial statements, price targets, institutional (13F) holdings and related news for FibroBiologics, Inc. Common Stock are updated in real time on BlackAll Trade.
FibroBiologics, Inc. Common Stock trades at $1.43 (-3.70%). Real-time quotes and charts are available on BlackAll Trade.
FibroBiologics, Inc. Common Stock has a market cap of about $0.01B.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's